2016 Hematological Malignancies

Previous Page

Next Page

Page Background

188 (26%)

540 (74%)

PET-positive:

PET-negative:

*Patients qualified for the PET question

PET evaluated by PET panel

HD15-PET trial

Activity of residual masses ≥ 2.5cm by PET (n=728)*